Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis

Fig. 5

Pooled estimates of the network meta-analysis in the second-line setting. A Pooled HRs (95% CIs) for PFS (upper triangle) and OS (lower triangle). B Pooled OR (95% CIs) for adverse events of grade 3 or higher (upper triangle) and overall response rate (lower triangle). Data in each cell are HRs or ORs (95% CIs) for comparing row-defined versus column-defined treatment in the upper triangle, and for comparing column-defined treatment in the lower triangle. Significant results are in bold. Abbreviations: HR, hazard ratio; CI, confidence interval; OR, odd ratio; Nivolu, Nivolumab; Ipilimu, Ipilimumab; Camrelizu, Camrelizumab; Pembrolizu, Pembrolizumab; Toripali, Toripalimab; Sintili, Sintilimab; chemo, chemotherapy

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us